/EWTX
EWTX Stock - Edgewise Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$25.55+20.80%
+$4.40 (+20.80%) • Dec 19
57
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.98
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).7
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-21.7%upside
Target: $20.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for EWTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$25.29 – $25.81
TARGET (TP)$20.00
STOP LOSS$23.51
RISK/REWARD1:-2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.27
52W High$30.65
52W Low$10.60
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $-185,000 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-158,832,000 | $-114,357,000 | $-71,658,000 | $-43,215,000 | $-17,192,000 |
| Net Income | $-133,813,000 | $-100,163,000 | $-67,640,000 | $-42,813,000 | $-17,054,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-1.45 | $-1.57 | $-1.26 | $-0.86 | $-0.35 |
Company Overview
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Visit WebsiteRating Distribution
Strong Buy
1
10%
Buy / Outperform
6
60%
Hold / Neutral
2
20%
Sell / Underperform
1
10%
Analyst Consensus🟢 Bullish
7 Bullish3 Neutral/Bearish
Price Targets
$34
Average Target
↑ 32.4% Upside
Now
$5
Low
$34
Average
$50
High
Based on 11 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 25th 2025 | Goldman | Initiation | Neutral | $20 |
| July 30th 2025 | Raymond James | Initiation | Strong Buy | $46 |
| June 30th 2025 | H.C. Wainwright | Initiation | Buy | $42 |
| April 30th 2025 | Guggenheim | Initiation | Buy | $41 |
| April 2nd 2025 | Scotiabank | Downgrade | Sector Perform | $14 |
| March 7th 2025 | Scotiabank | Initiation | Sector Outperform | $50 |
| January 22nd 2025 | Stifel | Initiation | Hold | $30 |
| November 22nd 2024 | Evercore ISI | Initiation | Outperform | $45 |
| March 7th 2024 | Piper Sandler | Initiation | Overweight | $48 |
| May 1st 2023 | Truist | Initiation | Buy | - |
| August 25th 2022 | Goldman | Downgrade | Sell | $5 |
| April 13th 2022 | RBC Capital Mkts | Initiation | Outperform | $31 |
Earnings History & Surprises
EWTXBeat Rate
67%
Last 18 quarters
Avg Surprise
+2.6%
EPS vs Estimate
Beats / Misses
12/6
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q1 24
-6.8%
$-0.47vs$-0.44
Q2 24
+15.4%
$-0.33vs$-0.39
Q3 24
+5.6%
$-0.34vs$-0.36
Q4 24
+2.7%
$-0.36vs$-0.37
Q1 25
-7.7%
$-0.42vs$-0.39
Q2 25
+4.4%
$-0.43vs$-0.45
Q3 25
+19.0%
$-0.34vs$-0.42
Q4 25
+2.5%
$-0.39vs$-0.40
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 2, 2026 | $-0.43 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.40 | $-0.39 | +2.5% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.42 | $-0.34 | +19.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.43 | +4.4% | ✓ BEAT |
Q1 2025 | Mar 3, 2025 | $-0.39 | $-0.42 | -7.7% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.37 | $-0.36 | +2.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.36 | $-0.34 | +5.6% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.39 | $-0.33 | +15.4% | ✓ BEAT |
Q1 2024 | Feb 22, 2024 | $-0.44 | $-0.47 | -6.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.40 | $-0.41 | -2.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.41 | $-0.34 | +17.1% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.37 | $-0.36 | +2.7% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-0.36 | $-0.31 | +13.9% | ✓ BEAT |
Q4 2022 | Nov 3, 2022 | $-0.36 | $-0.34 | +5.6% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.34 | $-0.32 | +5.9% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.29 | $-0.30 | -3.4% | ✗ MISS |
Q1 2022 | Feb 24, 2022 | $-0.28 | $-0.26 | +7.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.22 | $-0.26 | -18.2% | ✗ MISS |
Q3 2021 | Aug 9, 2021 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Latest News
Edgewise Therapeutics shares are trading higher after JP Mprgan raised its price target on the stock from $33 to $34.
📈 PositiveBenzinga•Nov 14, 2025, 05:10 PM
JP Morgan Maintains Overweight on Edgewise Therapeutics, Raises Price Target to $34
📈 PositiveBenzinga•Nov 14, 2025, 03:44 PM
Edgewise Therapeutics Appoints Michael Nofi As CFO; Succeeds R. Michael Carruthers
➖ NeutralBenzinga•Nov 10, 2025, 01:14 PM
RBC Capital Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50
📈 PositiveBenzinga•Nov 7, 2025, 06:55 PM
Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $32
➖ NeutralBenzinga•Nov 7, 2025, 03:05 PM
Edgewise Therapeutics Q3 EPS $(0.39) Beats $(0.40) Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:30 PM
JP Morgan Maintains Overweight on Edgewise Therapeutics, Lowers Price Target to $30
➖ NeutralBenzinga•Aug 19, 2025, 02:31 PM•Also:
Edgewise falls after data for muscular dystrophy therapy
📉 NegativeSeeking Alpha•Jun 26, 2025, 02:20 PM
Frequently Asked Questions about EWTX
What is EWTX's current stock price?
Edgewise Therapeutics, Inc. (EWTX) is currently trading at $25.55 per share. The stock has moved +20.80% today.
What is the analyst price target for EWTX?
The average analyst price target for EWTX is $20.00, based on 1 analyst.
What sector is Edgewise Therapeutics, Inc. in?
Edgewise Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is EWTX's market cap?
Edgewise Therapeutics, Inc. has a market capitalization of $2.70 billion, making it a mid-cap company.
Does EWTX pay dividends?
No, Edgewise Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
GLPG
Galapagos N.V.
$32.36
Mkt Cap: $2.1B
GPCR
Structure Therapeutics Inc.
$64.94
Mkt Cap: $3.7B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MESO
Mesoblast Limited
$19.48
Mkt Cap: $2.5B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OCUL
Ocular Therapeutix, Inc.
$12.56
Mkt Cap: $2.2B
QURE
uniQure N.V.
$23.99
Mkt Cap: $1.3B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
VRDN
Viridian Therapeutics, Inc.
$31.92
Mkt Cap: $2.6B
Explore stocks similar to EWTX for comparison